Lumanity Acquires Endpoint Outcomes, Creating a Single, Comprehensive Health Economics and Outcomes Research Offering



lumanity Aacquires Endpoint Results, VSto eat a Unique and complete Health Economics and Outcomes Research Offer

Oworld class results search capability teams up with existing expertise in health economics put patient voice at the center of drug development and demonstration of value

New York, June 14, 2022 – Lumanity today announced the acquisition of Endpoint Outcomes (“Endpoint”), a company specializing in harnessing the voice of patients to document the impact of treatments on quality of life related to health. The highly complementary acquisition of Endpoint Outcomes enhances Lumanity’s value demonstration capabilities by creating a comprehensive suite of health economics and outcomes research (“HEOR”) services.

Chris Evans, CEO of Endpoint Outcomes, said, “We are thrilled to join Lumanity and proud to be part of a company whose purpose aligns with ours. We have built a great organization and believe joining Lumanity is the next step on this journey, allowing us to continue to keep patients at the heart of everything we do. With new colleagues and capabilities to tap into, we now have the ingredients to create breakthrough solutions and drive even greater value for our customers and their patients.

Endpoint Outcomes is a leader in the development and implementation of patient-centered clinical outcome assessments (“COA”). Endpoint’s team of experts work with clients to help define the value of new medical innovations and generate the highest caliber evidence-based support for regulators, clinicians, payers and patients. The addition of Endpoint’s proven COA capability is critical to Lumanity’s mission to demonstrate the value of medical advancements to optimize patient access, which requires consideration and integration of economic, clinical and for patients. The convergence of health economics and patient-centric outcomes research is needed to support payer assessments and health technology assessments for Lumanity’s most important clients.

Jon Williams, CEO of Lumanity, said, “We are delighted to welcome Endpoint to Lumanity. We were immediately impressed with the strength of the team, the quality of Chris’s leadership and how our views aligned with the strategic opportunities available to us as a combined force. We look forward to working with our new colleagues to define and create cutting-edge patient-centric research services to meet the needs of both HTA and payers, and we are confident that our work will lead to new innovative solutions for our customers and partners.

Lumanity was created by bringing together the expertise and capabilities of several outstanding organizations, including Cello Health, BresMed, Guidemark Health, Cyan Health, Zipher Medical Affairs, and Innovative Edge. The addition of Endpoint Outcomes further enhances Lumanity’s unique and diverse collection of highly experienced industry pioneers, data luminaries, subject matter experts and proven problem solvers with clinical, scientific and functional capabilities advancements.


Pierre Marangos
+1 702 776 0985 /

About lumanity

Lumanity applies incisive thinking and decisive action to overcome complex situations and deliver transformative results to accelerate and optimize access to medical advances. With deep experience in medical, business and regulatory affairs, Lumanity transforms data and information into real-world insights and evidence that fuel successful commercialization and enable patients, providers, payers and regulators to make informed decisions. quick and decisive action.

With offices in North America, the UK, Europe and Asia, and work in over 50 countries, Lumanity has more than 1,200 experts working with leading pharmaceutical and biotechnology companies to: identify and generate the evidence needed to demonstrate the value of their products and bring them to patients at a price that reflects that value; translate science and data into compelling and relevant product stories for stakeholders around the world; and, enable business decisions that position these products for sustainable market success. Turning aspiration into reality, Lumanity helps deliver successful development strategies, payer submissions, commercial brand launches and product campaigns.

For more information, visit and connect with Lumanity on Twitter and LinkedIn

About Endpoint Results

Endpoint Outcomes is a scientific research and consulting company specializing in integrating the voice of patients into the drug development process to document the benefits of treatments on health-related quality of life and demonstrate the value of new medical innovations to regulators, clinicians and patients.

Founded in 2012 by Chris Evans, and with offices located in Boston, MA and Long Beach, CA, Endpoint Outcomes works with pharmaceutical and biotechnology companies to develop and validate outcome measures, prepare regulatory filings, provide regulatory advice, develop endpoint strategies, conduct literature reviews and gap analyses, and perform eCOA equivalency testing.

For more information, visit


About Author

Comments are closed.